Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-D-glucopyranosyl-2-carboxylic acid amide is a small molecule carbohydrate derivative belonging to the class of C-glycosyl compounds. It acts as an experimental inhibitor of glycogen phosphorylase (muscle form), an enzyme involved in glycogen breakdown. By inhibiting this enzyme, it has potential utility in modulating glucose metabolism and may be relevant for research into metabolic diseases such as diabetes. The compound has not been approved for clinical use and remains at the experimental stage[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-D-glucopyranosyl-2-carboxylic acid amide.